ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
+6.92%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$108M
AUM Growth
+$108M
(+6.4%)
Cap. Flow
+$1.51M
Cap. Flow
% of AUM
1.39%
Top 10 Holdings %
Top 10 Hldgs %
50.36%
Holding
47
New
11
Increased
13
Reduced
10
Closed
12
Top Buys
| 1 |
DaVita
DVA
|
$5.26M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$4.39M |
| 3 |
Incyte
INCY
|
$3.41M |
| 4 |
Insmed
INSM
|
$3.26M |
| 5 |
Pfizer
PFE
|
$3.01M |
Top Sells
| 1 |
OPTN
OptiNose
OPTN
|
$9.4M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$7.82M |
| 3 |
Exact Sciences
EXAS
|
$5.08M |
| 4 |
Quest Diagnostics
DGX
|
$2.7M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
$2.18M |
Sector Composition
| 1 | Healthcare | 86.09% |
| 2 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
PTC Therapeutics
PTCT
$3.92B
| $8.13M | 7.51% | 173,010 -32,021 | -16% | -$1.5M |
|
|
2
Insmed
INSM
$28.8B
| $7.28M | 6.73% | 360,182 +161,381 | +81% | +$3.26M |
|
|
PTLA
3
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $6.71M | 6.2% | 251,881 +164,765 | +189% | +$4.39M |
|
4
Acadia Healthcare
ACHC
$2.12B
| $6.57M | 6.07% | 186,631 +58,391 | +46% | +$2.06M |
|
|
5
DaVita
DVA
$9.85B
| $5.26M | 4.86% | +73,471 | New | +$5.26M |
|
|
AERI
6
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $4.49M | 4.15% | 72,970 +23,214 | +47% | +$1.43M |
|
7
Amicus Therapeutics
FOLD
$2.34B
| $4.33M | 4% | 358,191 +226,031 | +171% | +$2.73M |
|
8
UnitedHealth
UNH
$281B
| $4.08M | 3.77% | 15,344 +892 | +6% | +$237K |
|
|
GBT
9
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.93M | 3.63% | 103,449 +54,094 | +110% | +$2.06M |
|
10
Jazz Pharmaceuticals
JAZZ
$7.75B
| $3.72M | 3.44% | 22,144 -7,481 | -25% | -$1.26M |
|
11
Centene
CNC
$14.3B
| $3.6M | 3.33% | 24,862 -14,196 | -36% | -$2.06M |
|
|
12
Incyte
INCY
$16.5B
| $3.41M | 3.15% | +49,420 | New | +$3.41M |
|
13
AnaptysBio
ANAB
$569M
| $3.31M | 3.06% | 33,211 -7,507 | -18% | -$749K |
|
|
14
Pfizer
PFE
$141B
| $3.01M | 2.78% | +68,311 | New | +$3.01M |
|
15
Natera
NTRA
$23.1B
| $2.98M | 2.75% | 124,517 +5,648 | +5% | +$135K |
|
16
Neurocrine Biosciences
NBIX
$13.8B
| $2.84M | 2.63% | 23,133 -3,777 | -14% | -$464K |
|
17
CVS Health
CVS
$92.8B
| $2.82M | 2.61% | +35,870 | New | +$2.82M |
|
18
OraSure Technologies
OSUR
$242M
| $2.77M | 2.56% | +179,496 | New | +$2.77M |
|
|
19
Vertex Pharmaceuticals
VRTX
$100B
| $2.44M | 2.25% | 12,650 -40,558 | -76% | -$7.82M |
|
20
Sarepta Therapeutics
SRPT
$1.78B
| $2.34M | 2.16% | 14,508 +3,259 | +29% | +$526K |
|
|
XLRN
21
DELISTED
Acceleron Pharma Inc.
XLRN
| $2.28M | 2.11% | 39,912 +17,354 | +77% | +$993K |
|
|
NCNA
22
NuCana
NCNA
$6.09M
| $2.18M | 2.01% | 87,321 +39,449 | +82% | +$983K |
|
|
VRAY
23
DELISTED
ViewRay, Inc.
VRAY
| $2.1M | 1.94% | 223,885 -166,683 | -43% | -$1.56M |
|
24
Penumbra
PEN
$10.6B
| $1.97M | 1.82% | +13,187 | New | +$1.97M |
|
25
Ionis Pharmaceuticals
IONS
$6.8B
| $1.91M | 1.76% | +37,021 | New | +$1.91M |
|